Pulmonary Hypertension in Chronic Lung Diseases

Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with comb...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2013-12, Vol.62 (25), p.D109-D116
Main Authors: Seeger, Werner, MD, Adir, Yochai, MD, Barberà, Joan Albert, MD, Champion, Hunter, MD, PhD, Coghlan, John Gerard, MD, Cottin, Vincent, MD, De Marco, Teresa, MD, Galiè, Nazzareno, MD, Ghio, Stefano, MD, Gibbs, Simon, MD, Martinez, Fernando J., MD, Semigran, Marc J., MD, Simonneau, Gerald, MD, Wells, Athol U., MD, Vachiéry, Jean-Luc, MD
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular
Chronic Disease
combined pulmonary fibrosis and emphysema
COPD
exhausted circulatory reserve
exhausted ventilatory reserve
Heart
Human health and pathology
Humans
Hypertension, Pulmonary - diagnosis
Hypertension, Pulmonary - epidemiology
Hypertension, Pulmonary - therapy
Internal Medicine
Life Sciences
Lung Diseases, Interstitial - diagnosis
Lung Diseases, Interstitial - epidemiology
Lung Diseases, Interstitial - therapy
lung fibrosis
Medical sciences
Pneumology
Pulmonary Disease, Chronic Obstructive - diagnosis
Pulmonary Disease, Chronic Obstructive - epidemiology
Pulmonary Disease, Chronic Obstructive - therapy
Pulmonary Fibrosis - diagnosis
Pulmonary Fibrosis - epidemiology
Pulmonary Fibrosis - therapy
pulmonary hypertension in chronic lung disease
Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
Pulmonology and respiratory tract
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1 PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] 
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2013.10.036